
26 March 2025
GenIP Plc
("GenIP" or the "Company")
Contract Win
GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce it has secured a contract worth approximately USD$65,000 with a Singapore-based research institute (the "Client").
This contract, covering the delivery of 100 GenAI-enhanced analytical assessments, is part of a wider bid process with leading Asian institutions referred to in GenIP's announcement 13 March 2025.
The award results from GenIP's ongoing sponsorship of key technology transfer initiatives and marketing activities in leading Southeast Asian technology hubs.
Analytical assessment revenue will be recognised upon report production by GenIP and delivery to the Client.
Melissa Cruz, CEO of GenIP, commented:
"We are delighted to partner with a leading research and innovation institution in Singapore to accelerate the commercialisation of new technological discoveries. This collaboration demonstrates the broad application of our technology evaluation services by supporting cutting-edge clinical and healthcare research and innovation. Furthermore, this contract underscores the significant size of the addressable market for our technology commercialisation services."
For further information regarding GenIP, please visit www.genip.ai, or contact:
GenIP Plc Melissa Cruz, CEO | | Via Redchurch Communications |
| | |
Redchurch Communications (Financial PR) John Casey
| |
|
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.